While brentuximab has shown significant efficacy against some CD30+ malignancies such as HL (40, 41), the 5-year survival rate still remains unacceptable in relapsed/refractory patients (13), there are significant short- and long-term toxicities, and efficacy in CD30+ solid malignancies has been limited. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.